/
Ophthalmology
Macular Degeneration
60
Pipeline Programs↗
126
Active Trials↗
87
Companies Involved↗
Macular Degeneration is a moderately active landscape with 60 programs across 87 companies. The most active players are Biogen, EyeBiotech Ltd., Novartis. 11 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical22
Phase 112
Phase 215
Phase 311
Approved
No programs
Analysis
Modality Breakdown
84%
Small molecule
38 of 45 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 45 classified programs, each share of the total. Modality classified for 87% of 60 pipeline programs.
Analysis
Trial Status
560
clinical trials
Completed311 · 56%
Recruiting68 · 12%
Terminated55 · 10%
Unknown status46 · 8%
Active, not recruiting38 · 7%
Withdrawn20 · 4%
Other22 · 4%
Clinical Trials
Trial Activity
560 trials
Page 1 of 38
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)